Publication | Closed Access

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

Surgical OncologyMedicineCancer ManagementMelanomaClinical TrialsAdjuvant DabrafenibResectable MelanomaSurgeryDermatologyCancer TreatmentOncologyRadiation OncologyMolecular OncologyHealth Sciences